Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

7 terminated/withdrawn out of 28 trials

Success Rate

61.1%

-25.4% vs industry average

Late-Stage Pipeline

4%

1 trials in Phase 3/4

Results Transparency

73%

8 of 11 completed trials have results

Key Signals

6 recruiting8 with results6 terminated

Enrollment Performance

Analytics

Phase 2
17(65.4%)
Phase 1
7(26.9%)
N/A
1(3.8%)
Phase 3
1(3.8%)
26Total
Phase 2(17)
Phase 1(7)
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials
NCT07116174Not ApplicableRecruiting

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

Role: collaborator

NCT04504942Phase 2Completed

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Role: collaborator

NCT06828666Phase 1Recruiting

A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

Role: collaborator

NCT03877796Recruiting

Clinical Pre-screening Protocol for Ovarian Cancer

Role: collaborator

NCT05494697Phase 2Suspended

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Role: collaborator

NCT04098744Phase 2Recruiting

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Role: collaborator

NCT03902522Phase 2Completed

PRO 140 in Treatment-Experienced HIV-1 Subjects

Role: collaborator

NCT03838367Phase 1Terminated

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

Role: collaborator

NCT03878849Phase 2Recruiting

Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

Role: collaborator

NCT05571969Phase 1Suspended

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Role: collaborator

NCT04313400Phase 1Completed

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Role: collaborator

NCT05592418Phase 2Completed

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Role: collaborator

NCT04678830Phase 2Completed

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

Role: collaborator

NCT04426201Phase 2Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

Role: collaborator

NCT04669808Phase 2Completed

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma

Role: collaborator

NCT02737306Phase 2Terminated

A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation

Role: collaborator

NCT05844787Phase 1Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

Role: collaborator

NCT02175680Phase 2Completed

Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

Role: collaborator

NCT05730673Phase 2Withdrawn

Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Role: collaborator

NCT04293679Phase 1Completed

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC

Role: collaborator